Clinical Trials Logo

Myasthenia Gravis clinical trials

View clinical trials related to Myasthenia Gravis.

Filter by:

NCT ID: NCT06064695 Recruiting - Clinical trials for Generalized Myasthenia Gravis

Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Myasthenia Gravis

Start date: July 12, 2023
Phase: N/A
Study type: Interventional

During this pilot study, the investigators will examine the effects of whole-body electrical muscle stimulation exercise (WB-EMS Exercise) on neuromuscular junction (NMJ) transmission and fatigability in adults with Generalized Myasthenia Gravis (gMG). The investigators will also test whether a relationship exists between NMJ transmission dysfunction and fatigability in gMG, which has long been presumed but never directly assessed. Participants will undergo clinical and electrophysiologic testing before and after the WB-EMS Exercise intervention. The WB-EMS Exercise intervention will be delivered 2 times per week for 4 weeks. The hypotheses are (a) that the WB-EMS exercise will improve fatigability and NMJ transmission, and (b) that NMJ transmission dysfunction is related to fatigability.

NCT ID: NCT06064461 Not yet recruiting - Myasthenia Gravis Clinical Trials

Vitaccess Real MG Registry

VRMG
Start date: March 2024
Phase:
Study type: Observational

Vitaccess Real MG (VRMG) is a patient registry designed to capture longitudinal observational data on myasthenia gravis (MG), its treatment, and impact on symptoms, daily activities, and quality of life (QoL). The duration of the registry is 10 years from launch, and approximately 600 patients will be recruited in the US and Europe with no defined upper limit. The registry will link relevant patient- and healthcare professional (HCP)-reported data with clinical data from medical records. Patients will be recruited at clinical sites in all participating countries. In the US only, patients can additionally be recruited via community neurologists or direct-to-patient recruitment.

NCT ID: NCT06055959 Recruiting - Clinical trials for Generalized Myasthenia Gravis

A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

ziMyG
Start date: June 11, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to assess the pharmacokinetics, pharmacodynamics, safety, tolerability, immunogenicity and activity of zilucoplan (ZLP) in pediatric study participants with generalized myasthenia gravis (gMG).

NCT ID: NCT06006832 Recruiting - Myasthenia Gravis Clinical Trials

A Prospective Cohort Study of Myasthenia Gravis in China

Start date: August 20, 2023
Phase:
Study type: Observational

The goal of this prospective cohort study is to investigate long-term therapeutic strategies for myasthenia gravis (MG) and identify potential biomarkers. The main questions it aims to answer are: 1. Whether low-dose oral steroids may lead to a reduction in the recurrence rate among patients with MG. 2. To identify potential biomarkers that can predict disease progression and prognosis. This study recruits well-controlled patients with MG. Based on patient preferences and considerations such as coexisting conditions (e.g., uncontrolled hypertension, diabetes, severe osteoporosis, obesity), the participants will be non-randomly divided into two groups: a maintenance steroid therapy group and a withdrawal group (withdraw all immunosuppresants). Subsequently, these groups of patients will undergo long-term follow-up assessments.

NCT ID: NCT06002945 Recruiting - Myasthenia Gravis Clinical Trials

Exploring Outcomes and Characteristics of Myasthenia Gravis 2

EXPLORE-MG2
Start date: January 12, 2021
Phase:
Study type: Observational [Patient Registry]

The goal of this prospective observational study is to create a network repository of clinical data and biological samples to help researchers learn more about myasthenia gravis.

NCT ID: NCT05992025 Recruiting - Myasthenia Gravis Clinical Trials

Digital Phenotyping and Lifestyle Intervention in Patients With Myasthenia Gravis

DIG-MG
Start date: July 10, 2023
Phase: N/A
Study type: Interventional

Myasthenia Gravis (MG) is a chronic autoimmune neurological disorder where an antibody attack of muscle receptors causes fatigable skeletal muscle weakness. In addition to fatigue, several MG patients experience general fatigue. Small supervised studies during 12 weeks of physical exercise interventions have indicated safety and beneficial neuromuscular outcomes in MG patients. Longer and unsupervised studies are required to obtain guidelines for physical activity in MG patients. Further, the development of smart rings enables remote digital supervision of physical activity, sleep, and biological parameters such as heart frequency, number of steps, and temperature. These parameters could add to the lack of biomarkers in MG. The project design is a randomized controlled trial with a lifestyle intervention to improve fatigue in the autoimmune neuromuscular disease Myasthenia Gravis (MG). The intervention includes digital group counseling regarding physical activity, sleep, general health, and digital follow-up with a "smart ring" (OURA).

NCT ID: NCT05945784 Completed - Multiple Sclerosis Clinical Trials

Exploring Accessible Beauty for Individuals With Upper Extremity Deficits

Start date: July 21, 2023
Phase:
Study type: Observational

The purpose of this study is to investigate the accessibility of beauty products for individuals with upper extremity disabilities. By examining various factors such as packaging design, product applicators, and ease of use, this research aims to identify barriers faced by individuals with upper extremity disabilities or visual deficits when using beauty products. The study seeks to provide insights and recommendations for improving the accessibility of beauty products, ultimately promoting inclusivity and enhancing the overall beauty experience for individuals with disabilities.

NCT ID: NCT05919407 Recruiting - Myasthenia Gravis Clinical Trials

Pyridostigmine and Amifampridine for Myasthenia Gravis

IMPACT-MG
Start date: March 22, 2023
Phase: Phase 3
Study type: Interventional

A randomized, double-blind, placebo controlled, crossover intervention study evaluating the effect of pyridostigmine (part 1) and amifampridine (part 2) in Myasthenia Gravis (MG).

NCT ID: NCT05917184 Completed - Myasthenia Gravis Clinical Trials

The Adapting Disease Specific Outcome Measures Pilot Trial for Telehealth in Myasthenia Gravis

ADAPT-teleMG
Start date: August 30, 2021
Phase:
Study type: Observational

The goal of this pilot study is to determine the reliability of myasthenia gravis (MG) specific outcome measures obtained during virtual encounters with patients with myasthenia gravis. The main question it aims to answer is: Are MG-specific outcome measures obtained during virtual encounters reliable? Participants will complete two virtual study visits in which they will be administered common MG-specific outcome measures and a newly developed outcome measure developed specifically for telemedicine assessments of MG patients.

NCT ID: NCT05890833 Recruiting - Myasthenia Gravis Clinical Trials

The Risk of Falls Index for Patients With Neuromuscular Disorders

Start date: September 1, 2023
Phase:
Study type: Observational

The combination of short quantitatively assessing muscular function and balance in combination with short clinical scores, can be a new valid approach to evaluate the patient risk of fall and help to create a quick checkup test to prescribe an appropriate assistive device. The primary goal of this project is to provide a short battery of clinical assessments used to determine risk of falling for patients with neuromuscular diseases (NMD) based on correlation between clinical assessments between two groups of NMD patients and scales used to assess risk of falling for patients.